Multi-Variant Pathway Association Analysis Reveals the Importance of Genetic Determinants of Estrogen Metabolism in Breast and Endometrial Cancer Susceptibility

Despite the central role of estrogen exposure in breast and endometrial cancer development and numerous studies of genes in the estrogen metabolic pathway, polymorphisms within the pathway have not been consistently associated with these cancers. We posit that this is due to the complexity of multiple weak genetic effects within the metabolic pathway that can only be effectively detected through multi-variant analysis. We conducted a comprehensive association analysis of the estrogen metabolic pathway by interrogating 239 tagSNPs within 35 genes of the pathway in three tumor samples. The discovery sample consisted of 1,596 breast cancer cases, 719 endometrial cancer cases, and 1,730 controls from Sweden; and the validation sample included 2,245 breast cancer cases and 1,287 controls from Finland. We performed admixture maximum likelihood (AML)–based global tests to evaluate the cumulative effect from multiple SNPs within the whole metabolic pathway and three sub-pathways for androgen synthesis, androgen-to-estrogen conversion, and estrogen removal. In the discovery sample, although no single polymorphism was significant after correction for multiple testing, the pathway-based AML global test suggested association with both breast (p global = 0.034) and endometrial (p global = 0.052) cancers. Further testing revealed the association to be focused on polymorphisms within the androgen-to-estrogen conversion sub-pathway, for both breast (p global = 0.008) and endometrial cancer (p global = 0.014). The sub-pathway association was validated in the Finnish sample of breast cancer (p global = 0.015). Further tumor subtype analysis demonstrated that the association of the androgen-to-estrogen conversion sub-pathway was confined to postmenopausal women with sporadic estrogen receptor positive tumors (p global = 0.0003). Gene-based AML analysis suggested CYP19A1 and UGT2B4 to be the major players within the sub-pathway. Our study indicates that the composite genetic determinants related to the androgen–estrogen conversion are important for the induction of two hormone-associated cancers, particularly for the hormone-driven breast tumour subtypes.

[1]  C. Lewis,et al.  A critical evaluation of genomic control methods for genetic association studies , 2009, Genetic epidemiology.

[2]  M. Thun,et al.  Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 , 2009, Nature Genetics.

[3]  Julian Peto,et al.  Association of ESR1 gene tagging SNPs with breast cancer risk. , 2009, Human molecular genetics.

[4]  Päivi Heikkilä,et al.  NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer , 2008, Nature Genetics.

[5]  E. Winer,et al.  Advances in adjuvant endocrine therapy for postmenopausal women. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Chanock,et al.  Genetic variation in CYP17 and endometrial cancer risk , 2008, Human Genetics.

[7]  Kai Wang,et al.  Pathway-based approaches for analysis of genomewide association studies. , 2007, American journal of human genetics.

[8]  P. Yin,et al.  Aromatase excess in cancers of breast, endometrium and ovary , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[10]  X. Shu,et al.  Polymorphisms in the CYP19A1 (Aromatase) Gene and Endometrial Cancer Risk in Chinese Women , 2007, Cancer Epidemiology Biomarkers & Prevention.

[11]  Jaana M. Hartikainen,et al.  A common coding variant in CASP8 is associated with breast cancer risk , 2007, Nature Genetics.

[12]  Alison M Dunning,et al.  Association between Common Variation in 120 Candidate Genes and Breast Cancer Risk , 2007, PLoS genetics.

[13]  A. Neugut,et al.  Reproductive factors and breast cancer risk among older women , 2006, Breast Cancer Research and Treatment.

[14]  Paul D P Pharoah,et al.  The admixture maximum likelihood test: a novel experiment‐wise test of association between disease and multiple SNPs , 2006, Genetic epidemiology.

[15]  M. Pike,et al.  Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies , 2006, Breast Cancer Research.

[16]  M M Iles,et al.  Obtaining Unbiased Estimates of Tagging SNP Performance , 2006, Annals of human genetics.

[17]  B. Henderson,et al.  Estrogen Metabolism–Related Genes and Breast Cancer Risk: The Multiethnic Cohort Study , 2005, Cancer Epidemiology Biomarkers & Prevention.

[18]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[19]  Päivi Heikkilä,et al.  Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients , 2005, International journal of cancer.

[20]  J. Houck,et al.  Genetic Factors in Catechol Estrogen Metabolism in Relation to the Risk of Endometrial Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[21]  S. Hankinson,et al.  Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. , 2004, Journal of the National Cancer Institute.

[22]  A. Sokolenko,et al.  CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. , 2004, Cancer letters.

[23]  Nicholas W Wood,et al.  Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: implications for linkage-disequilibrium gene mapping. , 2003, American journal of human genetics.

[24]  Christopher A. Haiman,et al.  Choosing Haplotype-Tagging SNPS Based on Unphased Genotype Data Using a Preliminary Sample of Unrelated Subjects with an Example from the Multiethnic Cohort Study , 2003, Human Heredity.

[25]  T. Mack,et al.  Puberty and genetic susceptibility to breast cancer in a case-control study in twins. , 2003, The New England journal of medicine.

[26]  Zhaohui S. Qin,et al.  Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. , 2002, American journal of human genetics.

[27]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[28]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[29]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[30]  F. Clavel-Chapelon,et al.  Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women , 2002, British Journal of Cancer.

[31]  P. Kyyrönen,et al.  Survival of breast cancer patients in BRCA1, BRCA2, and non‐BRCA1/2 breast cancer families: A relative survival analysis from Finland , 2001, International journal of cancer.

[32]  H. Nevanlinna,et al.  A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families , 2001, British Journal of Cancer.

[33]  K Holli,et al.  Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. , 2000, Journal of the National Cancer Institute.

[34]  C. Ambrosone,et al.  Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. , 2000, Journal of the National Cancer Institute. Monographs.

[35]  H. Nevanlinna,et al.  Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? , 2000, European journal of cancer.

[36]  Chen-Yang Shen,et al.  Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. , 1999, Cancer research.

[37]  I Persson,et al.  Risk of endometrial cancer following estrogen replacement with and without progestins. , 1999, Journal of the National Cancer Institute.

[38]  H. Adami,et al.  Breast‐cancer risk following long‐term oestrogen‐ and oestrogen‐progestin‐replacement therapy , 1999, International journal of cancer.

[39]  O. Kallioniemi,et al.  Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. , 1997, Human molecular genetics.

[40]  S. Devries,et al.  Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. , 1994, The American journal of pathology.